MA53881A - Dérivés de pyrido[4,3-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2 - Google Patents

Dérivés de pyrido[4,3-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2

Info

Publication number: MA53881A
Authority: MA; Morocco
Prior art keywords: idh1; oxazin; pyrido; inhibitors; derivatives
Prior art date: 2016-12-16

Application number

MA053881A

Other languages

English (en)

Inventor

Renato Alejandro Bauer

Serge Louis Boulet

Timothy Paul Burkholder

Raymond Gilmour

Patric James Hahn

Zoran Rankovic

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-12-16

Filing date

2017-12-08

Publication date

2022-04-27

2017-12-08 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2022-04-27 Publication of MA53881A publication Critical patent/MA53881A/fr

Links

101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 title 1
101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 title 1
101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 title 1
102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 title 1
102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
UAQLXVHFTVTPBK-UHFFFAOYSA-N pyrido[4,3-d][1,3]oxazin-2-one Chemical class N=1C(OC=C2C=1C=CN=C2)=O UAQLXVHFTVTPBK-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Hematology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

MA053881A 2016-12-16 2017-12-08 Dérivés de pyrido[4,3-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2 MA53881A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201662435283P	2016-12-16	2016-12-16

Publications (1)

Publication Number	Publication Date
MA53881A true MA53881A (fr)	2022-04-27

Family

ID=60888651

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA47399A MA47399B1 (fr)	2016-12-16	2017-12-08	Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2
MA053881A MA53881A (fr)	2016-12-16	2017-12-08	Dérivés de pyrido[4,3-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
MA47399A MA47399B1 (fr)	2016-12-16	2017-12-08	Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2

Country Status (37)

Country	Link
US (3)	US11001596B2 (fr)
EP (2)	EP3555105B1 (fr)
JP (1)	JP6793836B2 (fr)
KR (1)	KR102276022B1 (fr)
CN (2)	CN115109075B (fr)
AU (2)	AU2017378060B2 (fr)
CA (1)	CA3045303C (fr)
CL (1)	CL2019001551A1 (fr)
CO (1)	CO2019005287A2 (fr)
CR (1)	CR20190252A (fr)
CY (1)	CY1123577T1 (fr)
DK (1)	DK3555105T3 (fr)
DO (1)	DOP2019000163A (fr)
EA (1)	EA036112B1 (fr)
EC (1)	ECSP19042682A (fr)
ES (2)	ES2941631T3 (fr)
HR (1)	HRP20201882T1 (fr)
HU (1)	HUE052067T2 (fr)
IL (1)	IL267236B (fr)
JO (1)	JOP20190142B1 (fr)
LT (1)	LT3555105T (fr)
MA (2)	MA47399B1 (fr)
MD (1)	MD3555105T2 (fr)
MX (1)	MX385562B (fr)
MY (1)	MY197313A (fr)
NZ (1)	NZ754115A (fr)
PE (1)	PE20190977A1 (fr)
PH (1)	PH12019501328B1 (fr)
PL (1)	PL3555105T3 (fr)
PT (1)	PT3555105T (fr)
RS (1)	RS61108B1 (fr)
SA (1)	SA519401897B1 (fr)
SI (1)	SI3555105T1 (fr)
TN (1)	TN2019000158A1 (fr)
UA (1)	UA123640C2 (fr)
WO (1)	WO2018111707A1 (fr)
ZA (1)	ZA201903125B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3194383B1 (fr)	2014-09-19	2019-11-06	Forma Therapeutics, Inc.	Compositions de quinoléinone pyrimidines en tant qu'inhibiteurs d'isocitrate déshydrogénase mutante
MA53352A (fr)	2014-09-19	2021-09-15	Forma Therapeutics Inc	Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase
MX372964B (es)	2014-09-19	2020-03-27	Forma Therapeutics Inc	Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh)
AU2015317327B9 (en)	2014-09-19	2020-04-09	Forma Therapeutics, Inc.	Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US9624175B2 (en)	2015-04-21	2017-04-18	Forma Therapeutics, Inc.	Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US10407419B2 (en)	2015-04-21	2019-09-10	Forma Therapeutics, Inc.	Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
EP3640251B1 (fr)	2016-10-24	2021-12-08	Astrazeneca AB	Dérivés de 6,7,8,9-tétrahydro-3h-pyrazolo[4,3-f]isoquinoléine utiles dans le traitement du cancer
JP7291077B2 (ja)	2016-12-16	2023-06-14	ヤンセンファーマシューティカエヌ．ベー．	Ｊａｋファミリーのキナーゼの低分子阻害物質
ES2941631T3 (es) *	2016-12-16	2023-05-24	Lilly Co Eli	Compuestos de Pirido[4,3-d][1,3]oxazin-2-ona como inhibidores de IDH1 e IDH2 mutantes
JOP20190144A1 (ar)	2016-12-16	2019-06-16	Janssen Pharmaceutica Nv	إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
PL3494116T3 (pl)	2017-01-30	2020-04-30	Astrazeneca Ab	Modulatory receptora estrogenowego
US11013734B2 (en)	2018-05-16	2021-05-25	Forma Therapeutics, Inc.	Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US20210196701A1 (en)	2018-05-16	2021-07-01	Forma Therapeutics, Inc.	Inhibiting mutant idh-1
WO2019222551A1 (fr)	2018-05-16	2019-11-21	Forma Therapeutics, Inc.	Formes solides de ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl) éthyl)amino)-1-méthyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11013733B2 (en)	2018-05-16	2021-05-25	Forma Therapeutics, Inc.	Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US11311527B2 (en)	2018-05-16	2022-04-26	Forma Therapeutics, Inc.	Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
TW202016110A (zh)	2018-06-15	2020-05-01	比利時商健生藥品公司	Ｊａｋ激酶家族之小分子抑制劑
CN115038700B (zh) *	2019-11-08	2025-07-25	内尔维亚诺医疗科学公司	偕二取代的杂环化合物及其作为idh抑制剂的用途
MX2022011846A (es) *	2020-03-23	2023-01-04	Lilly Co Eli	Metodo para el tratamiento de sujetos resistentes al inhibidor idh1.
CN115443137B (zh) *	2020-03-23	2024-05-31	伊莱利利公司	使用突变idh抑制剂和bcl-2抑制剂的组合疗法
AU2021242260B2 (en) *	2020-03-23	2023-12-14	Eli Lilly And Company	Combination therapy with a mutant IDH inhibitor
MX2022013258A (es)	2020-04-24	2022-11-14	Astrazeneca Ab	Formulaciones farmaceuticas.
MX2022013391A (es)	2020-04-24	2022-11-30	Astrazeneca Ab	Pauta posologica para el tratamiento del cancer.
US12559505B2 (en)	2020-06-28	2026-02-24	Wigen Biomedicine Technology (shanghai) Co., Ltd.	IDH mutant inhibitor and use thereof
WO2022020281A1 (fr)	2020-07-20	2022-01-27	Eli Lilly And Company	Polythérapie avec un inhibiteur d'idh1 mutant, un analogue de désoxyadénosine et un agent à base de platine
MX2023010642A (es)	2021-03-11	2023-11-28	Janssen Pharmaceutica Nv	Lorpucitinib para uso en el tratamiento de trastornos mediados por jak.
CN113588768B (zh) *	2021-05-18	2022-07-05	国家卫生健康委科学技术研究所	一种以分子图像方式定量组织内内源性代谢物的质谱方法
US20240261294A1 (en) *	2021-06-09	2024-08-08	Eli Lilly And Company	Method for treating idh inhibitor-resistant subjects
CA3217608A1 (fr)	2021-06-15	2022-12-22	Yuli Xie	Inhibiteur de mutant d'idh et son utilisation
US11746115B2 (en)	2021-08-13	2023-09-05	Eli Lilly And Company	Solid forms of 7-[[(1S)-1-[4-[(1S)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one
WO2023141087A1 (fr)	2022-01-19	2023-07-27	Eli Lilly And Company	Polythérapie avec un inhibiteur d'idh mutant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112014007310A2 (pt) *	2011-09-27	2017-04-04	Novartis Ag	3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
AU2014229283B2 (en) *	2013-03-14	2016-07-28	Novartis Ag	3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
WO2014147586A1 (fr) *	2013-03-22	2014-09-25	Novartis Ag	1-(2-(éthylamino)pyrimidin-4-yl)pyrrolidin-2-ones en tant qu'inhibiteurs du mutant idh
US9624175B2 (en) *	2015-04-21	2017-04-18	Forma Therapeutics, Inc.	Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
CN107405687A (zh) *	2015-04-24	2017-11-28	哈利伯顿能源服务公司	制作陶瓷或金属间化合物零件的方法
ES2764523T3 (es) *	2015-07-27	2020-06-03	Lilly Co Eli	Compuestos de 7-feniletilamino-4H-pirimido[4,5-D][1,3]oxazin-2-ona y su uso como inhibidores de IDH1 mutantes
CN109311863B (zh) *	2016-06-06	2021-10-29	伊莱利利公司	突变型idh1抑制剂
ES2941631T3 (es) *	2016-12-16	2023-05-24	Lilly Co Eli	Compuestos de Pirido[4,3-d][1,3]oxazin-2-ona como inhibidores de IDH1 e IDH2 mutantes

2017
- 2017-12-08 ES ES20189241T patent/ES2941631T3/es active Active
- 2017-12-08 PH PH1/2019/501328A patent/PH12019501328B1/en unknown
- 2017-12-08 WO PCT/US2017/065246 patent/WO2018111707A1/fr not_active Ceased
- 2017-12-08 KR KR1020197016855A patent/KR102276022B1/ko active Active
- 2017-12-08 MY MYPI2019003350A patent/MY197313A/en unknown
- 2017-12-08 RS RS20201429A patent/RS61108B1/sr unknown
- 2017-12-08 CA CA3045303A patent/CA3045303C/fr active Active
- 2017-12-08 EA EA201991161A patent/EA036112B1/ru not_active IP Right Cessation
- 2017-12-08 DK DK17822882.1T patent/DK3555105T3/da active
- 2017-12-08 NZ NZ754115A patent/NZ754115A/en unknown
- 2017-12-08 LT LTEP17822882.1T patent/LT3555105T/lt unknown
- 2017-12-08 PL PL17822882T patent/PL3555105T3/pl unknown
- 2017-12-08 UA UAA201905584A patent/UA123640C2/uk unknown
- 2017-12-08 CR CR20190252A patent/CR20190252A/es unknown
- 2017-12-08 SI SI201730488T patent/SI3555105T1/sl unknown
- 2017-12-08 MA MA47399A patent/MA47399B1/fr unknown
- 2017-12-08 US US16/349,873 patent/US11001596B2/en active Active
- 2017-12-08 CN CN202210758386.7A patent/CN115109075B/zh active Active
- 2017-12-08 MA MA053881A patent/MA53881A/fr unknown
- 2017-12-08 MD MDE20191188T patent/MD3555105T2/ro unknown
- 2017-12-08 EP EP17822882.1A patent/EP3555105B1/fr active Active
- 2017-12-08 JO JOP/2019/0142A patent/JOP20190142B1/ar active
- 2017-12-08 CN CN201780078017.0A patent/CN110072867B/zh active Active
- 2017-12-08 MX MX2019006830A patent/MX385562B/es unknown
- 2017-12-08 AU AU2017378060A patent/AU2017378060B2/en active Active
- 2017-12-08 TN TNP/2019/000158A patent/TN2019000158A1/en unknown
- 2017-12-08 ES ES17822882T patent/ES2835281T3/es active Active
- 2017-12-08 JP JP2019532088A patent/JP6793836B2/ja active Active
- 2017-12-08 PT PT178228821T patent/PT3555105T/pt unknown
- 2017-12-08 PE PE2019001077A patent/PE20190977A1/es unknown
- 2017-12-08 HR HRP20201882TT patent/HRP20201882T1/hr unknown
- 2017-12-08 HU HUE17822882A patent/HUE052067T2/hu unknown
- 2017-12-08 EP EP20189241.1A patent/EP3763717B1/fr active Active
2019
- 2019-05-17 ZA ZA2019/03125A patent/ZA201903125B/en unknown
- 2019-05-23 CO CONC2019/0005287A patent/CO2019005287A2/es unknown
- 2019-05-30 SA SA519401897A patent/SA519401897B1/ar unknown
- 2019-06-06 CL CL2019001551A patent/CL2019001551A1/es unknown
- 2019-06-11 DO DO2019000163A patent/DOP2019000163A/es unknown
- 2019-06-11 IL IL267236A patent/IL267236B/en active IP Right Grant
- 2019-06-14 EC ECSENADI201942682A patent/ECSP19042682A/es unknown
2020
- 2020-10-29 AU AU2020260493A patent/AU2020260493B2/en active Active
- 2020-11-25 CY CY20201101122T patent/CY1123577T1/el unknown
2021
- 2021-03-16 US US17/202,867 patent/US11629156B2/en active Active
- 2021-03-16 US US17/202,515 patent/US11649247B2/en active Active

Also Published As

Publication number	Publication date
JP2020502157A (ja)	2020-01-23
EP3555105A1 (fr)	2019-10-23
JOP20190142B1 (ar)	2023-03-28
ZA201903125B (en)	2024-08-28
PH12019501328A1 (en)	2020-02-24
CL2019001551A1 (es)	2019-10-25
HUE052067T2 (hu)	2021-04-28
WO2018111707A1 (fr)	2018-06-21
CR20190252A (es)	2019-08-26
DOP2019000163A (es)	2019-07-15
PH12019501328B1 (en)	2023-05-12
ECSP19042682A (es)	2019-06-30
KR102276022B1 (ko)	2021-07-13
SA519401897B1 (ar)	2022-07-28
EP3763717B1 (fr)	2023-03-08
US11629156B2 (en)	2023-04-18
JOP20190142A1 (ar)	2019-06-13
JP6793836B2 (ja)	2020-12-02
AU2017378060B2 (en)	2020-09-03
ES2835281T3 (es)	2021-06-22
LT3555105T (lt)	2021-01-11
MA47399B1 (fr)	2021-02-26
MD3555105T2 (ro)	2021-01-31
IL267236B (en)	2020-08-31
HRP20201882T1 (hr)	2021-01-22
CY1123577T1 (el)	2022-03-24
UA123640C2 (uk)	2021-05-05
ES2941631T3 (es)	2023-05-24
AU2020260493A1 (en)	2020-11-26
MX385562B (es)	2025-03-18
CN110072867A (zh)	2019-07-30
CN115109075A (zh)	2022-09-27
RS61108B1 (sr)	2020-12-31
EA036112B1 (ru)	2020-09-29
PE20190977A1 (es)	2019-07-09
US20200079791A1 (en)	2020-03-12
TN2019000158A1 (en)	2020-10-05
CO2019005287A2 (es)	2019-05-31
MA47399A (fr)	2019-10-23
EP3555105B1 (fr)	2020-10-28
US20210230185A1 (en)	2021-07-29
MX2019006830A (es)	2019-08-22
CA3045303A1 (fr)	2018-06-21
CN110072867B (zh)	2022-07-08
NZ754115A (en)	2021-07-30
CA3045303C (fr)	2022-05-17
PL3555105T3 (pl)	2021-05-17
US11001596B2 (en)	2021-05-11
US20210206780A1 (en)	2021-07-08
SI3555105T1 (sl)	2020-12-31
KR20190077539A (ko)	2019-07-03
MY197313A (en)	2023-06-13
EA201991161A1 (ru)	2019-11-29
IL267236A (en)	2019-08-29
BR112019009648A2 (pt)	2019-09-10
AU2020260493B2 (en)	2021-09-09
EP3763717A1 (fr)	2021-01-13
DK3555105T3 (da)	2020-11-09
CN115109075B (zh)	2024-09-20
US11649247B2 (en)	2023-05-16
PT3555105T (pt)	2020-12-21
AU2017378060A1 (en)	2019-05-30

Publication	Publication Date	Title
MA53881A (fr)	2022-04-27	Dérivés de pyrido[4,3-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2
MA46339A (fr)	2019-08-07	Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30
MA46981A (fr)	2019-10-09	Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA48994A (fr)	2020-02-05	Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
EA201791692A1 (ru)	2018-01-31	4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
MA46470A (fr)	2019-08-14	1h-imidazo[4,5-b]pyridin-2(3h)-ones substituées et leur utilisation en tant que modulateurs du récepteur glun2b
MX390630B (es)	2025-03-21	Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
EP3416964A4 (fr)	2019-09-18	Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk
IL263947B (en)	2022-10-01	Compositions and methods for making benzylisoquinoline alkaloids, morphinan alkaloids, thebaine, and derivatives thereof
HUE053027T2 (hu)	2021-06-28	Stabilizált, szolúbilis prefúziós RSV F fehérje, RSV-fertõzés megelõzésében történõ alkalmazásra
MX386328B (es)	2025-03-18	Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
MA46264A (fr)	2019-07-31	Dérivés pyrazolo[1,5-a]pyridine et leur utilisation en tant qu'agents de lutte antiparasitaire
ME03672B (fr)	2020-10-20	1h-pyrazolo [4,3-b]pyridines en tant qu'inhibiteurs de pde1
MA54448A (fr)	2021-10-20	Dérivés naphthyridine et quinoléine en tant qu'inhibiteurs de alk5
EP3515914A4 (fr)	2020-04-15	Nouvelles imidazo[1,5-a]pyridines substituées en position 5 ou 8 en tant qu'indoleamine et/ou tryptophane 2,3-dioxygénases
EP3328379A4 (fr)	2019-06-19	Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines
EP3380475A4 (fr)	2019-07-03	Dérivés d'octahydropyrrolo [3, 4-c
EP3402793A4 (fr)	2019-10-09	Dérivés de pyridazine en tant qu'activateurs d'eaat2
MX2018002416A (es)	2018-11-29	Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
EP3487851A4 (fr)	2019-12-25	Dérivés de l'aminopyridine et leur utilisation en tant qu'inhibiteurs sélectifs d'alk-2
MA52722A (fr)	2021-04-14	Dérivés d'oxazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation
MA53432A (fr)	2021-06-30	Imidazo[1,2-b]pyridazines utilisées en tant qu'inhibiteurs de trk
MA47593A (fr)	2020-01-01	Dérivés de 1, 4, 6-trisubstitué-2-alkyl-1h-benzo[d]imidazole en tant qu'inhibiteurs de dihydroorotate oxygénase
MA54101A (fr)	2021-10-27	Dérivés de thiazine et d'oxazine bicycliques en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation
DK3452465T3 (da)	2021-02-08	Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme